Deficiencies in current evaluations of the cost-effectiveness of biologic agents for RA

Nat Clin Pract Rheumatol. 2009 Feb;5(2):78-9. doi: 10.1038/ncprheum0985. Epub 2008 Dec 23.
No abstract available

MeSH terms

  • Antirheumatic Agents / economics*
  • Antirheumatic Agents / therapeutic use
  • Arthritis, Rheumatoid / drug therapy
  • Arthritis, Rheumatoid / economics*
  • Arthritis, Rheumatoid / physiopathology
  • Cost-Benefit Analysis
  • Humans
  • Immunologic Factors / economics*
  • Immunologic Factors / therapeutic use
  • Quality-Adjusted Life Years

Substances

  • Antirheumatic Agents
  • Immunologic Factors